ArticleScientific reports2026
Impact of regulatory changes on the use of baclofen in alcohol use disorders between 2014 and 2021, using the French National Health Data System.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The off-label use of baclofen in the treatment of alcohol use disorders (AUD) increased significantly between 2007 and 2013 in France. In March 2014, a temporary recommendation for use (TRU) was granted, followed by a marketing authorization (MA) in October 2018. In July 2017, the maximum dose was limited to 80 mg/day to limit serious adverse effects related to high doses in a 3rd version of the TRU. The aim of this study was to assess the impact of regulatory changes on baclofen initiations for AUD and compliance with daily dose recommendations between 2014 and 2021 using the French National Health Data System. Time series analyses were performed to evaluate the MA effect and 3rd TRU on initiations and daily doses. A total of 478,109 patients initiated baclofen for AUD between 2014 and 2021. After a maximum in initiations in 2014 ((N = 98,552), initiations declined gradually (N = 48,471 in 2021). The MA had no impact on initiations. The 3rd TRU helped to reduce the number of patients with a high dose, even if majority of patients had doses of less than 80 mg/day (78.0% before vs. 88.3% after 3rd TRU). Regulatory measures have therefore had a slight impact on the use of baclofen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.